The global market for Cannabis Pharmaceuticals was estimated at US$5.2 Billion in 2024 and is projected to reach US$72.7 Billion by 2030, growing at a CAGR of 55.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Cannabis Pharmaceuticals market.
Segments: Brand (Sativex Brand, Epidiolex Brand, Other Brands)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Cannabis Pharmaceuticals Market - Key Trends & Drivers Summarized
Why Is Cannabis Gaining Recognition in the Pharmaceutical Industry?
Cannabis-based pharmaceuticals are emerging as a transformative segment within the global healthcare industry, driven by increasing scientific validation of cannabinoids for medical applications. The legalization of medical cannabis in numerous countries has fueled research and development (R&D) efforts, leading to the approval of cannabis-derived drugs for conditions such as epilepsy, multiple sclerosis, and chronic pain. Additionally, shifting regulatory frameworks and growing physician acceptance are paving the way for cannabis-based formulations to be integrated into mainstream healthcare.How Are Advancements in Cannabis Research Expanding Pharmaceutical Applications?
Ongoing clinical research has uncovered the therapeutic potential of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC), leading to the development of prescription cannabis-based drugs. Pharmaceutical companies are investing in cannabinoid extraction and formulation technologies to enhance bioavailability, stability, and targeted delivery. Advances in nanotechnology and encapsulation methods are improving the efficacy of oral, transdermal, and inhalable cannabis medications. Additionally, the exploration of minor cannabinoids such as cannabigerol (CBG) and cannabinol (CBN) is expanding the therapeutic scope of cannabis pharmaceuticals, potentially leading to new treatments for neurodegenerative diseases, anxiety disorders, and autoimmune conditions.Which Therapeutic Areas Are Driving the Demand for Cannabis Pharmaceuticals?
The primary demand for cannabis-based pharmaceuticals comes from patients suffering from chronic pain, neurological disorders, and mental health conditions. Epidiolex, a CBD-based drug, has gained FDA approval for treating rare forms of epilepsy, while Sativex, an oral spray containing THC and CBD, is widely used for multiple sclerosis-related spasticity. The growing acceptance of cannabis for pain management is leading to its adoption as an alternative to opioids, particularly for cancer and arthritis patients. Additionally, ongoing research into cannabis-based treatments for anxiety, PTSD, and sleep disorders is expanding the potential applications of cannabis pharmaceuticals.What Are the Key Drivers Behind the Growth of the Cannabis Pharmaceuticals Market?
The growth in the cannabis pharmaceuticals market is driven by several factors, including expanding medical cannabis legalization, increased R&D investment, and growing patient demand for alternative treatments. Regulatory approvals for cannabis-based drugs in North America and Europe have legitimized the sector, encouraging pharmaceutical companies to develop new formulations. The opioid crisis has also contributed to the demand for non-addictive pain management solutions, positioning cannabis as a viable alternative. Additionally, advancements in drug delivery systems and precision dosing are improving the efficacy of cannabis-based medications, further accelerating market growth. As global healthcare systems continue to recognize the benefits of medical cannabis, the pharmaceutical cannabis sector is poised for significant expansion.Report Scope
The report analyzes the Cannabis Pharmaceuticals market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Brand (Sativex Brand, Epidiolex Brand, Other Brands)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Sativex Brand segment, which is expected to reach US$52.6 Billion by 2030 with a CAGR of a 60.1%. The Epidiolex Brand segment is also set to grow at 49.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $1.4 Billion in 2024, and China, forecasted to grow at an impressive 51.8% CAGR to reach $10.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Cannabis Pharmaceuticals Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cannabis Pharmaceuticals Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Cannabis Pharmaceuticals Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AbbVie Inc., Aphria Inc., Aurora Cannabis Inc., Bausch Health Companies Inc., Canopy Growth Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 48 Featured):
- AbbVie Inc.
- Aphria Inc.
- Aurora Cannabis Inc.
- Bausch Health Companies Inc.
- Canopy Growth Corporation
- Cresco Labs Inc.
- Cronos Group Inc.
- Curaleaf Holdings, Inc.
- Green Thumb Industries Inc.
- GW Pharmaceuticals
- Harvest Health & Recreation Inc.
- Hexo Corp.
- Insys Therapeutics, Inc.
- Jazz Pharmaceuticals plc
- MedReleaf Corp.
- Organigram Holdings Inc.
- Sundial Growers Inc.
- Tilray Brands, Inc.
- Trulieve Cannabis Corp.
- VIVO Cannabis Inc.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Aphria Inc.
- Aurora Cannabis Inc.
- Bausch Health Companies Inc.
- Canopy Growth Corporation
- Cresco Labs Inc.
- Cronos Group Inc.
- Curaleaf Holdings, Inc.
- Green Thumb Industries Inc.
- GW Pharmaceuticals
- Harvest Health & Recreation Inc.
- Hexo Corp.
- Insys Therapeutics, Inc.
- Jazz Pharmaceuticals plc
- MedReleaf Corp.
- Organigram Holdings Inc.
- Sundial Growers Inc.
- Tilray Brands, Inc.
- Trulieve Cannabis Corp.
- VIVO Cannabis Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 116 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 5.2 Billion |
| Forecasted Market Value ( USD | $ 72.7 Billion |
| Compound Annual Growth Rate | 55.1% |
| Regions Covered | Global |
